0001140361-20-008836.txt : 20200414 0001140361-20-008836.hdr.sgml : 20200414 20200414163654 ACCESSION NUMBER: 0001140361-20-008836 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200414 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200414 DATE AS OF CHANGE: 20200414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01136 FILM NUMBER: 20791698 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 8-K 1 form8k.htm CURRENT REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2020

BRISTOL-MYERS SQUIBB COMPANY
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)
001-01136
(Commission File Number)
22-0790350
(IRS Employer Identification Number)

430 East 29th Street, 14th Floor
New York, NY, 10016
(Address of Principal Executive Office)

Registrant’s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.10 Par Value
 BMY
New York Stock Exchange
1.000% Notes due 2025
BMY25
New York Stock Exchange
1.750% Notes due 2035
BMY35
New York Stock Exchange
Bristol-Myers Squibb Contingent Value Rights
BMY RT
New York Stock Exchange
Celgene Contingent Value Rights
 CELG RT
New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01
Other Events.

On April 14, 2020, Bristol-Myers Squibb Company (the “Company”) announced that, due to the public health concerns related to the coronavirus or COVID-19 pandemic, it is changing the location of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”), to be held on Tuesday, May 5, 2020 at 10:00 a.m. Eastern Time to a virtual-only meeting. Stockholders will not be able to attend the Annual Meeting in-person. A copy of the press release announcing the location change is attached hereto as Exhibit 99.1 and is incorporated by reference herein. Further information regarding this change to the location of the Annual Meeting can be found in the proxy supplement filed by the Company with the Securities and Exchange Commission on April 14, 2020.

Item 9.01.
Financial Statements and Exhibits.

(d) Exhibits

The following exhibit is included as part of this Current Report on Form 8-K:

Exhibit
No.
  
Description
     
99.1
  
Press release of Bristol-Myers Squibb Company dated April 14, 2020.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).




EXHIBIT INDEX

Exhibit
No.
  
Description
     
 
Press release of Bristol-Myers Squibb Company dated April 14, 2020.
     
104
  
The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BRISTOL-MYERS SQUIBB COMPANY
     
Dated: April 14, 2020
By:
/s/Katherine R. Kelly
 
Name:
Katherine R. Kelly
 
Title:
Corporate Secretary


EX-99.1 2 ex99_1.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY
Exhibit 99.1


Bristol Myers Squibb Announces Virtual 2020 Annual Meeting of Shareholders

NEW YORK – April 14, 2020 – Bristol Myers Squibb (NYSE: BMY) today announced that the Company will hold its 2020 Annual Meeting of Shareholders in a virtual-only format due to public health concerns relating to the coronavirus (COVID-19) and to protect the health and well-being of its shareholders, directors, employees and the public. As previously announced, the 2020 Annual Meeting will be held on May 5, 2020, at 10:00 a.m. Eastern Time.

Shareholders will not be able to attend the 2020 Annual Meeting in-person at a physical location.  However, the virtual 2020 Annual Meeting will provide shareholders of record as of the close of business on March 16, 2020, the ability to participate, vote their shares and ask questions during the meeting via audio webcast.

To be admitted to the virtual 2020 Annual Meeting, shareholders should visit www.virtualshareholdermeeting.com/BMY2020 and enter the 16-digit control number included on your Important Notice Regarding the Availability of Proxy Materials, on your proxy card, or on the instructions that accompanied your proxy materials.

Guests may join the virtual 2020 Annual Meeting in a listen-only mode. No control number is required.

Below are additional details on how shareholders can participate in the virtual 2020 Annual Meeting:


 •
Access the meeting platform beginning at 9:50 a.m. ET on May 5, 2020.

•
Vote during the 2020 Annual Meeting by following the instructions available on the meeting website during the meeting.

•
To submit a question before the meeting, visit www.proxyvote.com with your 16-digit control number and select the “Submit a Question for Management” option.

•
To submit a question during the meeting, visit www.virtualshareholdermeeting.com/BMY2020, enter your 16-digit control number and type your question into the “Ask a Question” field and click “Submit.”

•
The company will provide direct and specific information to shareholder proponents on how they can present their shareholder proposals during the meeting.

•
If you encounter any difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the Virtual Shareholder Meeting log in page. Technical support will be available beginning at 9:30 a.m. ET on May 5, 2020 and will remain available until the meeting has ended.

About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Bristol Myers Squibb Contacts
Media:
609-252-3345
media@bms.com

Investors:
Tim Power
609-252-7509
timothy.power@bms.com

Nina Goworek
908-673-9711
nina.goworek@bms.com


 EX-101.SCH 3 bmy-20200414.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information - 8-K link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 bmy-20200414_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bmy-20200414_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Amendment Flag City Area Code Entity Address, City or Town Entity Address, Country Document Period End Date Entity Incorporation, State or Country Code Entity Listings [Table] Local Phone Number Entity Address, Postal Zip Code Entity Address, State or Province Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Entity Listings [Line Items] Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Document Fiscal Year Focus Document Fiscal Period Focus Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity File Number Entity Emerging Growth Company Class of Stock [Domain] Common Stock [Member] Class of Stock [Axis] Bristol-Myers Squibb Contingent Value Rights [Member] 1.000% Notes due 2025 [Member] Celgene Contingent Value Rights [Member] 1.750% Notes due 2035 [Member] EX-101.PRE 6 bmy-20200414_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image00010.jpg begin 644 image00010.jpg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end XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 6, "dts": { "definitionLink": { "local": [ "bmy-20200414_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "form8k.htm" ] }, "labelLink": { "local": [ "bmy-20200414_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bmy-20200414_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bmy-20200414.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 38, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 4, "memberStandard": 1, "nsprefix": "bmy", "nsuri": "http://bms.com/20200414", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20200414to20200414", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information - 8-K", "role": "http://bms.com/role/DocumentAndEntityInformation8K", "shortName": "Document and Entity Information - 8-K", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "form8k.htm", "contextRef": "c20200414to20200414", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 5, "tag": { "bmy_BristolMyersSquibbContingentValueRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Bristol-Myers Squibb Contingent Value Rights [Member]" } } }, "localname": "BristolMyersSquibbContingentValueRightsMember", "nsuri": "http://bms.com/20200414", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "domainItemType" }, "bmy_CelgeneContingentValueRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Celgene Contingent Value Rights [Member]" } } }, "localname": "CelgeneContingentValueRightsMember", "nsuri": "http://bms.com/20200414", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "domainItemType" }, "bmy_One000NotesDue2025Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.000% Notes due 2025 [Member]" } } }, "localname": "One000NotesDue2025Member", "nsuri": "http://bms.com/20200414", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "domainItemType" }, "bmy_One750NotesDue2035Member": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "1.750% Notes due 2035 [Member]" } } }, "localname": "One750NotesDue2035Member", "nsuri": "http://bms.com/20200414", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityListingsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Listings [Line Items]" } } }, "localname": "EntityListingsLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "stringItemType" }, "dei_EntityListingsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container for exchange listing information for an entity", "label": "Entity Listings [Table]" } } }, "localname": "EntityListingsTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://bms.com/role/DocumentAndEntityInformation8K" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 11 form8k_htm.xml IDEA: XBRL DOCUMENT 0000014272 2020-04-14 2020-04-14 0000014272 bmy:CelgeneContingentValueRightsMember 2020-04-14 2020-04-14 0000014272 bmy:BristolMyersSquibbContingentValueRightsMember 2020-04-14 2020-04-14 0000014272 bmy:One750NotesDue2035Member 2020-04-14 2020-04-14 0000014272 us-gaap:CommonStockMember 2020-04-14 2020-04-14 0000014272 bmy:One000NotesDue2025Member 2020-04-14 2020-04-14 false 0000014272 8-K 2020-04-14 BRISTOL-MYERS SQUIBB COMPANY DE 001-01136 22-0790350 430 East 29th Street 14th Floor New York NY 10016 212 546-4000 false false false false Common Stock, $0.10 Par Value BMY NYSE 1.000% Notes due 2025 BMY25 NYSE 1.750% Notes due 2035 BMY35 NYSE Bristol-Myers Squibb Contingent Value Rights BMY RT NYSE Celgene Contingent Value Rights CELG RT NYSE false EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information - 8-K
Apr. 14, 2020
Entity Listings [Line Items]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 14, 2020
Entity Registrant Name BRISTOL-MYERS SQUIBB COMPANY
Entity Incorporation, State or Country Code DE
Entity File Number 001-01136
Entity Tax Identification Number 22-0790350
Entity Address, Address Line One 430 East 29th Street
Entity Address, Address Line Two 14th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10016
City Area Code 212
Local Phone Number 546-4000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000014272
Common Stock [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Common Stock, $0.10 Par Value
Trading Symbol BMY
Security Exchange Name NYSE
1.000% Notes due 2025 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.000% Notes due 2025
Trading Symbol BMY25
Security Exchange Name NYSE
1.750% Notes due 2035 [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security 1.750% Notes due 2035
Trading Symbol BMY35
Security Exchange Name NYSE
Bristol-Myers Squibb Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Bristol-Myers Squibb Contingent Value Rights
Trading Symbol BMY RT
Security Exchange Name NYSE
Celgene Contingent Value Rights [Member]  
Entity Listings [Line Items]  
Title of 12(b) Security Celgene Contingent Value Rights
Trading Symbol CELG RT
Security Exchange Name NYSE
ZIP 15 0001140361-20-008836-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-20-008836-xbrl.zip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end XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 6 95 1 false 5 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information - 8-K Sheet http://bms.com/role/DocumentAndEntityInformation8K Document and Entity Information - 8-K Cover 1 false false All Reports Book All Reports form8k.htm bmy-20200414.xsd bmy-20200414_def.xml bmy-20200414_lab.xml bmy-20200414_pre.xml ex99_1.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true false